hVIVO (LON:HVO) Earns "Buy" Rating from Shore Capital

hVIVO (LON:HVO - Get Free Report)'s stock had its "buy" rating reissued by research analysts at Shore Capital in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a GBX 35 ($0.47) target price on the stock. Shore Capital's price objective would indicate a potential upside of 254.43% from the company's current price.

hVIVO Stock Performance

HVO traded up GBX 0.13 ($0.00) during trading hours on Tuesday, hitting GBX 9.88 ($0.13). 901,723 shares of the stock were exchanged, compared to its average volume of 3,226,052. The stock has a 50-day simple moving average of GBX 12.01 and a 200-day simple moving average of GBX 15.27. hVIVO has a 12 month low of GBX 6.50 ($0.09) and a 12 month high of GBX 30.50 ($0.41). The stock has a market cap of £69.87 million, a price-to-earnings ratio of 4.07 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.